Résumé
Background: Limb muscle dysfunction is prevalent in chronic obstructive pulmonary disease (COPD) and has important clinical implications, such as reduced exercise tolerance, quality of life, and even survival. Since the last American Thoracic Society (ATS) and European Respiratory Society (ERS) statement on limb muscle dysfunction, important progress has been made in the characterization of this problem and on our understanding of its pathophysiolog-y and clinical implications.
Purpose: The purpose of this document is to update the 1999 ATS/ ERS statement on limb muscle dysfunction in COPD.
Methods: An interdisciplinary committee of experts from the ATS and ERS determined that the scope of this document should be limited to limb muscles. Committee members conducted focused reviews of the literature on relevant topics. A librarian also performed a literature search. An ATS methodologist provided advice to the committee, ensuring that the methodological approach was consistent with ATS standards.
Results: We identified important advances in our understanding of the extent and nature of the structural alterations hi limb muscles in patients with COPD. Since the last update, studies have been published regarding mechanisms of development of limb muscle dysfunction in COPD and on the treatment of this condition. The clinical implications of limb muscle dysfunction have been delineated. Although exercise training is the most potent intervention to address this condition, other therapies, such as neuromuscular electrical stimulation, are emerging. Assessment of limb muscle function can identify patients who are at increased risk of poor clinical outcomes, such as exercise intolerance and premature mortality.
Conclusions: Limb muscle dysfunction is a key systemic consequence of COPD. However, there are still important gaps in our knowledge about mechanisms of development of this problem. Strategies for early detection and specific treatments for this condition are needed.